When the cure kills—CBD limits biodiversity research
Author(s)
Prathapan, K Divakaran
Pethiyagoda, Rohan
Bawa, Kamaljit S
Raven, Peter H
Rajan, Priyadarsanan Dharma
Acosta, Luis E
Adams, Byron
Adl, Sina
Ahyong, Shane T
Anderson, Robert
Arango, Claudia P
Arnedo, Miquel A
Armbruster, Jonathan W
Javier Avila, Luciano
Azevedo, Celso O
Baldo, Diego
Barclay, Maxwell VL
Baron-Szabo, Rosemarie
Bauer, Aaron M
Bentlage, Bastian
Bezdek, Ales
Bird, Graham
Blagoderov, Vladimir
Bocak, Ladislav
Bonaldo, Alexandre
Bond, Jason E
Borkent, Christopher J
Branham, Marc A
Carranza, Salvador
Carreno, Ramon
de Carvalho, MR
Castroviejo-Fisher, Santiago
Chiba, Hideyuki
Ciampor, Fedor
Clarke, Dave J
Collins, Allen G
Constantino, Reginaldo
Crespo, Francisco A
Daly, Marymegan
Dominiak, Patrycja
Dronen, Norm
Dubois, Alain
Duda, Thomas F
Eleaume, Marc
Erlacher, Sven
Estrela, Pedro Cordeiro
Evenhuis, Neal
Fehlauer-Ale, Karin Hoch
Fery, Hans
Fritz, Uwe
Gaimari, Stephen D
Garrison, Rosser
Gaubert, Philippe
Geiger, Daniel L
Gill, Anthony C
Gimmel, Matthew L
Goldschmidt, Tom
Goswami, Rajkamal
Perez Gonzalez, Abel
Gonzalez, Victor H
Gordon, Dennis
Gower, David J
Greenslade, Penelope
Gusarov, Vladimir I
Hajdu, Eduardo
Harms, Danilo
Heinicke, Matthew P
Hilton, Eric J
Hodgson, CJ
Hormiga, Gustavo
Hughes, Lauren E
Hutchings, Pat
Jaeger, Peter
Jennings, John T
Kadej, Marcin
Kaila, Lauri
Kaminski, Marcin Jan
Karaman, GS
Karanovic, Tom
Kathirithamby, Jeyaraney
Kerr, Peter H
Kirkendall, Lawrence R
Kitahara, Marcelo Visentini
Klautau, Michelle
Kondratieff, Boris C
Kroh, Andreas
Labarque, Facundo M
Leavengood, John M
Letardi, Agostino
Liang, Ai-Ping
Lima, Flavio CT
Liu, Zhiwei
Lobl, Ivan
Lohrmann, Volker
Malchus, Nikolaus
Malipatil, MB
Marques, Antonio C
Matzke-Karasz, R
Mayer, Georg
Mayoral, Jaime G
McInnes, SJ
Minelli, Alessandro
Moir, Melinda L
Monks, Scott
Morrone, Juan J
Muster, C
Nagy, Zoltan Tamas
Narayanan, K Seena
Nearns, Eugenio H
Nekola, Jeff
Nihei, Silvio S
Nuetzel, Alexander
Ohler, Annemarie
Dill Orrico, Victor Goyannes
Padial, Jose M
Page, Lawrence M
Passos, Paulo
Paulson, Dennis
Perkins, Philip D
Pfingstl, Tobias
Prieto, Carlos
Pinheiro, Livia Rodrigues
Pinto-da-Rocha, Ricardo
Prendini, Lorenzo
Price, Benjamin
De Prins, Jurate
Ramirez, Martin
Rasmussen, Claus
Rasmussen, P
Redei, David
Ribera, Ignacio
Ricarte, Antonio
Rivera, Julio
Rix, Michael G
Rossaro, Bruno
Roy, Aniruddha Datta
Ruiz, Gustavo RS
Salles, Frederico F
Sanborn, Allen F
Sartori, Michel
Schoeller, Matthias
Schmelz, Rudiger M
Schroedl, Michael
Segniagbeto, Gabriel Hoinsoude
Serrano, J
Shimano, Satoshi
Shin, Mann Kyoon
Sidorchuk, Ekaterina
Siler, Cameron D
Sket, Boris
Smith, Aaron D
Smith, Andrew BT
Smith, Robin
Smith-Pardo, Allan H
Sparks, John
Sterrer, WE
Stroinski, Adam
Svavarsson, Jorundur
Toledo, Mario
Twomey, Evan
Vasudevan, Karthikeyan
Vences, Miguel
de Voogd, Nicole
Wang, Qiao
Watson, Gillian W
Weiner, Wanda M
Weksler, Marcelo
Wesener, Thomas
Whitmore, Daniel
Wiklund, Helena
Williams, Paul H
Winterton, Shaun L
Wood, Timothy S
Yen, Shen-Horn
Zaher, Hussam
Zhang, Z-Q
Zhou, Hong-zhang
Griffith University Author(s)
Year published
2018
Metadata
Show full item recordAbstract
The Convention on Biological Diversity (CBD) commits its 196 nation parties to conserve biological diversity, use its components sustainably, and share fairly and equitably the benefits from the utilization of genetic resources. The last of these objectives was further codified in the Convention's Nagoya Protocol (NP), which came into effect in 2014. Although these aspirations are laudable, the NP and resulting national ambitions on Access and Benefit Sharing (ABS) of genetic resources have generated several national regulatory regimes fraught with unintended consequences (1). Anticipated benefits from the commercial use of ...
View more >The Convention on Biological Diversity (CBD) commits its 196 nation parties to conserve biological diversity, use its components sustainably, and share fairly and equitably the benefits from the utilization of genetic resources. The last of these objectives was further codified in the Convention's Nagoya Protocol (NP), which came into effect in 2014. Although these aspirations are laudable, the NP and resulting national ambitions on Access and Benefit Sharing (ABS) of genetic resources have generated several national regulatory regimes fraught with unintended consequences (1). Anticipated benefits from the commercial use of genetic resources, especially those that might flow to local or indigenous communities because of regulated access to those resources, have largely been exaggerated and not yet realized. Instead, national regulations created in anticipation of commercial benefits, particularly in many countries that are rich in biodiversity, have curtailed biodiversity research by in-country scientists as well as international collaboration (1). This weakens the first and foremost objective of the CBD—conservation of biological diversity. We suggest ways that the Conference of the Parties (CoP) of the CBD may proactively engage scientists to create a regulatory environment conducive to advancing biodiversity science.
View less >
View more >The Convention on Biological Diversity (CBD) commits its 196 nation parties to conserve biological diversity, use its components sustainably, and share fairly and equitably the benefits from the utilization of genetic resources. The last of these objectives was further codified in the Convention's Nagoya Protocol (NP), which came into effect in 2014. Although these aspirations are laudable, the NP and resulting national ambitions on Access and Benefit Sharing (ABS) of genetic resources have generated several national regulatory regimes fraught with unintended consequences (1). Anticipated benefits from the commercial use of genetic resources, especially those that might flow to local or indigenous communities because of regulated access to those resources, have largely been exaggerated and not yet realized. Instead, national regulations created in anticipation of commercial benefits, particularly in many countries that are rich in biodiversity, have curtailed biodiversity research by in-country scientists as well as international collaboration (1). This weakens the first and foremost objective of the CBD—conservation of biological diversity. We suggest ways that the Conference of the Parties (CoP) of the CBD may proactively engage scientists to create a regulatory environment conducive to advancing biodiversity science.
View less >
Journal Title
Science
Volume
360
Issue
6396
Subject
Conservation and biodiversity
Environmental management
Environmental and resources law
Environmental politics